source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…
- FDA approves GSK‑Ionis hepatitis B functional cure, Hibsago, targeting undetectable virus after six monthsThe FDA has approved bepirovirsen, an antisense oligonucleotide from GSK and Ionis, for chronic hepatitis B infection. It will be sold under the brand name Hibsago. The therapy is described as a f…